ArticleBMJ open2013
Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey.
Article in BMJ open, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Pooled it
- Improving adverse drug event reporting by healthcare professionals.The Cochrane database of systematic reviews · 2024Pooled it
- Trial
- The effect of a pharmacy-led transitional care program on medication-related problems post-discharge: A before-After prospective study.PloS one · 2019Trial
- Economic impact of medication management by clinical pharmacists in a urology department.Central European journal of urology · 2026Article
- Evaluating the economic impact of clinical pharmacist interventions in the women's health setting in Qatar.International journal of clinical pharmacy · 2025Article
- Prevalence and risk factors of self-reported adverse drug events in elderly co-morbid patients in northeastern China: a cross-sectional study.BMC geriatrics · 2025Article
- Development of Automated Triggers in Ambulatory Settings in Brazil: Protocol for a Machine Learning-Based Design Thinking Study.JMIR research protocols · 2024Article
- Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis.International journal of clinical pharmacy · 2024Article
- Prescribing cascades of antigout medications from thiazide diuretics in gout-naïve hypertensive adults receiving first-line pharmacological management.Scientific reports · 2024Article
- Database screening as a strategy to identify endogenous candidate metabolites to probe and assess mitochondrial drug toxicity.Scientific reports · 2023Article
- Exploring Australian pharmacists' views toward reducing the risk of medicines-related harm in aged care residents.Pharmacology research & perspectives · 2023Article
- Atopic Dermatitis Polypharmacy and Out-Of-Pocket Healthcare Expenses.Journal of drugs in dermatology : JDD · 2023Article
- Economic Burdens of Uncomplicated Malaria in Primary Health Care (PHC) Facilities of Plateau State, Nigeria: Patients' Perspectives.International journal of environmental research and public health · 2023Article
- Exploring Australian pharmacists' perceptions and practices towards reducing the risk of medicines-related harm in aged care residents.Frontiers in pharmacology · 2023Article
- Costs Associated with Adverse Drug Reactions Among HIV/TB Patients in Thailand.ClinicoEconomics and outcomes research : CEOR · 2022Article
- Drug-Therapy Problems and Predictors among Hospitalized Heart-Failure Patients: A Prospective Observational Study.Drug, healthcare and patient safety · 2020Article
- Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province.Frontiers in pharmacology · 2020Article
- Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature.European journal of clinical pharmacology · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the cost of illness (COI) of individuals with self-reported adverse drug events (ADEs) from a societal perspective and to compare these estimates with the COI for individuals without ADE. Furthermore, to estimate the direct costs resulting from two ADE categories, adverse drug reactions (ADRs) and subtherapeutic effects of medication therapy (STE).
designCross-sectional study.
settingThe adult Swedish general population.
participantsThe survey was distributed to a random sample of 14 000 Swedish residents aged 18 years and older, of which 7099 responded, 1377 reported at least one ADE and 943 reported an ADR or STE.
main outcome measuresSocietal COI, including direct and indirect costs, for individuals with at least one self-reported ADE, and the direct costs for prescription drugs and healthcare use resulting from self-reported ADRs and STEs were estimated during 30 days using a bottom-up approach.
resultsThe economic burden for individuals with ADEs were (95% CI) 442.7 to 599.8 international dollars (Int$), of which direct costs were Int$ 279.6 to 420.0 (67.1%) and indirect costs were Int$ 143.0 to 199.8 (32.9%). The average COI was higher among those reporting ADEs compared with other respondents (COI: Int$ 442.7 to 599.8 versus Int$ 185.8 to 231.2). The COI of respondents reporting at least one ADR or STE was Int$ 468.9 to 652.9. Direct costs resulting from ADRs or STEs were Int$ 15.0 to 48.4. The reported resource use occurred both in hospitals and outside in primary care.
conclusionsSelf-reported ADRs and STEs cause resource use both in hospitals and in primary care. Moreover, ADEs seem to be associated with high overall COI from a societal perspective when comparing respondents with and without ADEs. There is a need to further examine this relationship and to study the indirect costs resulting from ADEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.